Targeting HRAS in Head and Neck Cancer : Lessons From the Past and Future Promise
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved..
ABSTRACT: HRAS mutations define a unique biologic subset of head and neck squamous cell carcinoma. Oncogenic HRAS is uniquely dependent on posttranslational farnesylation for membrane localization and activation of downstream signaling. Tipifarnib, a farnesyltransferase inhibitor, demonstrated encouraging antitumor activity for HRAS mutant head and neck squamous cell carcinoma and modest activity for HRAS mutant salivary gland cancer. New combination strategies to circumvent intrinsic and acquired resistance to TFIs are being investigated.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Cancer journal (Sudbury, Mass.) - 28(2022), 5 vom: 27. Sept., Seite 363-368 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Desilets, Antoine [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biological Products |
|---|
| Anmerkungen: |
Date Completed 29.09.2022 Date Revised 17.08.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/PPO.0000000000000616 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346813662 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346813662 | ||
| 003 | DE-627 | ||
| 005 | 20231226032336.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/PPO.0000000000000616 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1155.xml |
| 035 | |a (DE-627)NLM346813662 | ||
| 035 | |a (NLM)36165724 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Desilets, Antoine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeting HRAS in Head and Neck Cancer |b Lessons From the Past and Future Promise |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.09.2022 | ||
| 500 | |a Date Revised 17.08.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a ABSTRACT: HRAS mutations define a unique biologic subset of head and neck squamous cell carcinoma. Oncogenic HRAS is uniquely dependent on posttranslational farnesylation for membrane localization and activation of downstream signaling. Tipifarnib, a farnesyltransferase inhibitor, demonstrated encouraging antitumor activity for HRAS mutant head and neck squamous cell carcinoma and modest activity for HRAS mutant salivary gland cancer. New combination strategies to circumvent intrinsic and acquired resistance to TFIs are being investigated | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 650 | 7 | |a Farnesyltranstransferase |2 NLM | |
| 650 | 7 | |a EC 2.5.1.29 |2 NLM | |
| 650 | 7 | |a HRAS protein, human |2 NLM | |
| 650 | 7 | |a EC 3.6.5.2 |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins p21(ras) |2 NLM | |
| 650 | 7 | |a EC 3.6.5.2 |2 NLM | |
| 700 | 1 | |a Ho, Alan L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer journal (Sudbury, Mass.) |d 2000 |g 28(2022), 5 vom: 27. Sept., Seite 363-368 |w (DE-627)NLM107294931 |x 1540-336X |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2022 |g number:5 |g day:27 |g month:09 |g pages:363-368 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/PPO.0000000000000616 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2022 |e 5 |b 27 |c 09 |h 363-368 | ||